Abstract
We assessed the combined antitumor activity of docetaxel and doxorubicin (DXR) and tetrahydropyranyladriamycin (THP) using the human breast carcinoma cell lines R-27 and MDA-MB-231. Synergistic antitumor activity was observed for both combined docetaxel and DXR, and docetaxel and THP against R-27 cells when contacted simultaneously. However, only additive effects were observed against MDA-MB-231 cells. Intracellular concentrations of DXR and THP in R-27 cells were significantly increased by docetaxel pretreatment, however, this increase was not observed in MDA-MB-231 cells, which exhibited only additive sensitivity to the treatment. Thus, docetaxel increased the antitumor activity of anthracyclines by increasing their intracellular concentrations.
| Original language | English |
|---|---|
| Pages (from-to) | 777-781 |
| Number of pages | 5 |
| Journal | Oncology Reports |
| Volume | 9 |
| Issue number | 4 |
| Publication status | Published - 2002 Jul |
Fingerprint
Keywords
- Breast cancer
- Combination therapy
- Docetaxel
- Doxorubicin
- Intracellular concentration
- Synergism
- Tetrahydropyranyladriamycin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation. / Egawa, Tomohisa; Kubota, Tetsuro; Suto, Akihiko; Otani, Yoshihide; Furukawa, Toshiharu; Watanabe, Masahiko; Kumai, Koichiro; Kitajima, Masaki.
In: Oncology Reports, Vol. 9, No. 4, 07.2002, p. 777-781.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation
AU - Egawa, Tomohisa
AU - Kubota, Tetsuro
AU - Suto, Akihiko
AU - Otani, Yoshihide
AU - Furukawa, Toshiharu
AU - Watanabe, Masahiko
AU - Kumai, Koichiro
AU - Kitajima, Masaki
PY - 2002/7
Y1 - 2002/7
N2 - We assessed the combined antitumor activity of docetaxel and doxorubicin (DXR) and tetrahydropyranyladriamycin (THP) using the human breast carcinoma cell lines R-27 and MDA-MB-231. Synergistic antitumor activity was observed for both combined docetaxel and DXR, and docetaxel and THP against R-27 cells when contacted simultaneously. However, only additive effects were observed against MDA-MB-231 cells. Intracellular concentrations of DXR and THP in R-27 cells were significantly increased by docetaxel pretreatment, however, this increase was not observed in MDA-MB-231 cells, which exhibited only additive sensitivity to the treatment. Thus, docetaxel increased the antitumor activity of anthracyclines by increasing their intracellular concentrations.
AB - We assessed the combined antitumor activity of docetaxel and doxorubicin (DXR) and tetrahydropyranyladriamycin (THP) using the human breast carcinoma cell lines R-27 and MDA-MB-231. Synergistic antitumor activity was observed for both combined docetaxel and DXR, and docetaxel and THP against R-27 cells when contacted simultaneously. However, only additive effects were observed against MDA-MB-231 cells. Intracellular concentrations of DXR and THP in R-27 cells were significantly increased by docetaxel pretreatment, however, this increase was not observed in MDA-MB-231 cells, which exhibited only additive sensitivity to the treatment. Thus, docetaxel increased the antitumor activity of anthracyclines by increasing their intracellular concentrations.
KW - Breast cancer
KW - Combination therapy
KW - Docetaxel
KW - Doxorubicin
KW - Intracellular concentration
KW - Synergism
KW - Tetrahydropyranyladriamycin
UR - http://www.scopus.com/inward/record.url?scp=0036635917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036635917&partnerID=8YFLogxK
M3 - Article
C2 - 12066208
AN - SCOPUS:0036635917
VL - 9
SP - 777
EP - 781
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -